Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nyse  >  Bristol-Myers Squibb Company    BMY

News SummaryMost relevantAll newsSector newsTweets

Biocon, Bristol-Myers Squibb Sign Pact for Experimental Oral Insulin Drug

share with twitter share with LinkedIn share with facebook
share via e-mail
11/16/2012 | 05:26am CEST
   By Rumman Ahmed 

BANGALORE, India--Biocon Ltd. (532523.BY) Friday said it has entered into an agreement with Bristol-Myers Squibb Co. (>> Bristol Myers Squibb Co.) on a licensing deal for its experimental biopharmaceutical drug IN-105, which is an orally administered insulin.

Under the terms of the agreement, the New York-headquartered company will have the right to exercise an option to obtain a global license for IN-105 on the successful completion of mid-stage trials for the experimental drug by Biocon, the Indian company said in a statement.

Biocon, which develops biological treatments that use proteins manufactured in living cells, is India's largest biotechnology company by revenue.

It has been seeking alliances with other drug makers for further development of the experimental drug under a licensing agreement.

If Bristol-Myers Squibb decides to obtain the license for IN-105, the U.S. company will assume full responsibility for the development program, including all development and commercialization activities outside India, the statement said.

In return, Biocon will receive a license fee, potential payments when IN-105 achieves certain regulatory and commercial milestones, as well as royalties on commercial sales of IN-105 outside India, the statement added.

Biocon will retain exclusive rights to IN-105 in India.

Indian drug makers often seek to develop drugs in partnership with foreign companies because they can help finance costly and lengthy research. At the same time, global companies are keen to cooperate with Indian companies because of lower costs, the availability of skilled scientists in the South Asian country, as well as the prospect of adding new products to their portfolios.

Write to Rumman Ahmed at [email protected]

Subscribe to WSJ: http://online.wsj.com?mod=djnwires

Stocks mentioned in the article : Bristol Myers Squibb Co.
share with twitter share with LinkedIn share with facebook
share via e-mail
02:02p BRISTOL MYERS SQUIBB : Jimmy Smits Joins Stand Up to Cancer in New Public Servic..
10/20 BRISTOL MYERS SQUIBB : to Present New Data Advancing Research Across Serious Liv..
10/20 BRISTOL MYERS SQUIBB : U.S. Food and Drug Administration Accepts Bristol Myers S..
10/19 BRISTOL MYERS SQUIBB : Trevi Therapeutics Hires Dr. Helena Brett-Smith as Chief ..
10/19 BRISTOL MYERS SQUIBB : Stand Up To Cancer Awards Moffitt $2.67 Million to Study ..
10/19 BRISTOL MYERS SQUIBB : An Application for the Trademark "BEQSTIAT" Has Been File..
10/19 BRISTOL MYERS SQUIBB : BMY Extends Strategic Partnership with TARGET PharmaSolut..
10/18 JOHNSON & JOHNSON : Missouri appeals court throws out $72 million award in Johns..
10/17 BRISTOL MYERS SQUIBB : Hundreds of patients to have access to head and neck canc..
10/16 BRISTOL MYERS SQUIBB : U.S. Food and Drug Administration (FDA) Accepts Bristol-M..
More news
News from SeekingAlpha
10/20 The Market Is Skeptical About Roche Ahead Of Major Trial Read-Outs
10/20 3 THINGS, OCTOBER 20, 2017 : Gilead's Big Day, Celgene's Bad News In Crohn's, Br..
10/19 Market Is Not Waiting For Tax Reform - Cramer's Mad Money (10/18/17)
10/18 3 THINGS IN BIOTECH YOU SHOULD LEARN : October 18, 2017
10/18 Exploring AstraZeneca's Two-Prong Assault On Lung Cancer
Financials ($)
Sales 2017 20 540 M
EBIT 2017 5 540 M
Net income 2017 4 594 M
Debt 2017 237 M
Yield 2017 2,45%
P/E ratio 2017 23,23
P/E ratio 2018 21,47
EV / Sales 2017 5,15x
EV / Sales 2018 4,94x
Capitalization 106 B
Duration : Period :
Bristol-Myers Squibb Compa Technical Analysis Chart | BMY | US1101221083 | 4-Traders
Technical analysis trends BRISTOL-MYERS SQUIBB COMPA
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus HOLD
Number of Analysts 23
Average target price 60,7 $
Spread / Average Target -5,8%
EPS Revisions
Giovanni Caforio Chairman & Chief Executive Officer
Charles A. Bancroft CFO, EVP & Head-Global Business Operations
Paul von Autenried Chief Information Officer & Senior Vice President
Thomas James Lynch Chief Scientific Officer & Executive VP
Vicki L. Sato Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
JOHNSON & JOHNSON23.29%382 202
NOVARTIS13.50%226 404
PFIZER11.58%216 886
ROCHE HOLDING LTD.5.55%207 116